Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.

被引:12
|
作者
Sana, Talea [1 ]
Qayyum, Shaista [2 ]
Jabeen, Almas [2 ]
Siddiqui, Bina S. [1 ]
Begum, Sabira [1 ]
Siddiqui, Rafat A. [3 ]
Hadda, Taibi B. [4 ]
机构
[1] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[2] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[3] Virginia State Univ, Food Chem & Nutr Sci Res Lab, Petersburg, VA USA
[4] Univ Mohammed Premier, Fac Sci, Lab Chim Materiaux, Oujda 60000, Morocco
关键词
Anti-inflammatory; Anti-lymphoma; Nyctanthesin A; B; -Cells; Non -Hodgkin lymphoma; PHENYLETHANOID GLYCOSIDES; CANCER; ASSAY; PROLIFERATION; GROWTH; LEAVES;
D O I
10.1016/j.jep.2022.115267
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Nyctanthes arbor-tristis Linn. is native to Indo-Pak sub-continent and has high medicinal values in Ayureda. This plant has been used traditionally for the treatment of sciatica, rheumatism, chronic fever, diabetes, snakebite, dysentery, cachexia and cancer. Studies have shown many pharmacological properties such as anti-cancer efficacy against Dalton's ascetic lymphoma, cytotoxicity against T-cell leukemia, anti-inflammatory, anti-diabetic and anti-oxidant effects. Aim of the study:Aim of the study was to explore the anti-inflammatory and anti-proliferative potential of N. arbor-tristis.Material and methods: Ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis was used in the present study. A new compound nyctanthesin A was isolated following a bioactivity-guided fractionation and chro-matographic separations. Its chemical structure was elucidated through spectral studies including 1D, 2D-NMR experiments and HREIMS. The intracellular reactive oxygen species (ROS) and nitric oxide (NO) generation from phagocytes were detected by chemiluminescence technique and Griess method, respectively. TNF-alpha and TGF-fi production was quantified by ELISA. Anti-lymphoma and cytotoxic activities were assessed by alamar blue and MTT assays, respectively. The transcription and protein expression level of Bcl-2, COX-2, p38 MAPK, PDL-1, NF-Kappa B, c-Myc and PNF-Kappa B was performed by qRT-PCR and protein blot assays, respectively.Results: Petroleum ether insoluble fraction of the ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis revealed anti-inflammatory potential by inhibiting ROS. A previously undescribed compound nyctanthesin A was isolated from this fraction and characterized by UV, IR, NMR and HREIMS. It showed significant anti-inflammatory property by inhibiting ROS, NO and TNF-alpha production. The strong anti-proliferative effects on B-cell lymphoma cells, DOHH2 and Raji, revealed its anti-lymphoma potential along with non-toxic profile against BJ and NIH-3T3 fibroblast cells of normal origin. The qRT-PCR results showed marked inhibition of Bcl-2, COX-2, p38 MAPK, PDL-1, c-Myc, NF-Kappa B, and PNF-Kappa B at transcription level in DOHH2 cells with comparatively lesser but significant effects in Raji cells, where the expression of Bcl-2 gene was not affected. The protein expression of PNF-Kappa B in DOHH2 cells was inhibited by 66% (P < 0.05) and COX-2 in both cell lines was inhibited by 50% (P < 0.05) at 60 mu g/mL. A moderate non-significant inhibition of TGF-fi (~20%) was observed in both cell lines at 100 mu g/mL Conclusions: Scientific evidences reported here validate the anti-inflammatory and anti-cancer potential of the plant.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
    Cao, Yaqing
    Lu, Wenyi
    Sun, Rui
    Jin, Xin
    Cheng, Lin
    He, Xiaoyuan
    Wang, Luqiao
    Yuan, Ting
    Lyu, Cuicui
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [42] Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
    Vidal-Crespo, Anna
    Matas-Cespedes, Alba
    Rodriguez, Vanina
    Rossi, Cedric
    Valero, Juan G.
    Serrat, Neus
    Sanjuan-Pla, Alejandra
    Menendez, Pablo
    Roue, Gael
    Lopez-Guillermo, Armando
    Gine, Eva
    Campo, Elias
    Colomer, Dolors
    Bezombes, Christine
    van Bueren, Jeroen Lammerts
    Chiu, Christopher
    Doshi, Parul
    Perez-Galan, Patricia
    HAEMATOLOGICA, 2020, 105 (04) : 1032 - 1041
  • [43] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2010, 116 (21) : 1148 - 1149
  • [44] Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1; Dose-Escalation Study
    Herrera, Alex F.
    Patel, Manish R.
    Burke, John M.
    Advani, Ranjana
    Cheson, Bruce D.
    Sharman, Jeff P.
    Penuel, Elicia
    Polson, Andrew G.
    Di Liao, Chen
    Li, Chunze
    Schuth, Eva
    Vaze, Anjali
    Samineni, Divya
    Elstrom, Rebecca
    Cooper, James
    Diefenbach, Catherine
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1294 - 1301
  • [45] A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma
    Grossbard, ML
    Multani, PS
    Freedman, AS
    O'Day, S
    Gribben, JG
    Rhuda, C
    Neuberg, D
    Nadler, LM
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2392 - 2398
  • [46] Treatment of patients with mantle cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan™):: Evaluation of safety and response.
    Winkler, U
    Schulz, HR
    Klein, TO
    Jensen, M
    Manzke, O
    Schmitz, SH
    Rüdiger, T
    Müller-Hermelink, KH
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [47] 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Li, Ping
    Liu, Yang
    Liang, Yun
    Bo, Jian
    Gao, Sujun
    Hu, Yongxian
    Hu, Yu
    Huang, He
    Huang, Xiaojun
    Jing, Hongmei
    Ke, Xiaoyan
    Li, Jianyong
    Li, Yuhua
    Liu, Qifa
    Lu, Peihua
    Mei, Heng
    Niu, Ting
    Song, Yongping
    Song, Yuqin
    Su, Liping
    Tu, Sanfang
    Wang, Jianxiang
    Wu, Depei
    Wang, Zhao
    Xu, Kailin
    Ying, Zhitao
    Yang, Qingming
    Zhang, Yajing
    Shi, Fengxia
    Zhang, Bin
    Zhang, Huilai
    Zhang, Xi
    Zhao, Mingfeng
    Zhao, Weili
    Zhao, Xiangyu
    Huang, Liang
    Zhu, Jun
    Qian, Wenbin
    Han, Weidong
    Liang, Aibin
    CANCER BIOLOGY & MEDICINE, 2023, 20 (02) : 129 - 146
  • [48] 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Ping Li
    Yang Liu
    Yun Liang
    Jian Bo
    Sujun Gao
    Yongxian Hu
    Yu Hu
    He Huang
    Xiaojun Huang
    Hongmei Jing
    Xiaoyan Ke
    Jianyong Li
    Yuhua Li
    Qifa Liu
    Peihua Lu
    Heng Mei
    Ting Niu
    Yongping Song
    Yuqin Song
    Liping Su
    Sanfang Tu
    Jianxiang Wang
    Depei Wu
    Zhao Wang
    Kailin Xu
    Zhitao Ying
    Qingming Yang
    Yajing Zhang
    Fengxia Shi
    Bin Zhang
    Huilai Zhang
    Xi Zhang
    Mingfeng Zhao
    Weili Zhao
    Xiangyu Zhao
    Liang Huang
    Jun Zhu
    Wenbin Qian
    Weidong Han
    Aibin Liang
    Cancer Biology & Medicine, 2023, 20 (02) : 129 - 146
  • [49] 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Ping Li
    Yang Liu
    Yun Liang
    Jian Bo
    Sujun Gao
    Yongxian Hu
    Yu Hu
    He Huang
    Xiaojun Huang
    Hongmei Jing
    Xiaoyan Ke
    Jianyong Li
    Yuhua Li
    Qifa Liu
    Peihua Lu
    Heng Mei
    Ting Niu
    Yongping Song
    Yuqin Song
    Liping Su
    Sanfang Tu
    Jianxiang Wang
    Depei Wu
    Zhao Wang
    Kailin Xu
    Zhitao Ying
    Qingming Yang
    Yajing Zhang
    Fengxia Shi
    Bin Zhang
    Huilai Zhang
    Xi Zhang
    Mingfeng Zhao
    Weili Zhao
    Xiangyu Zhao
    Liang Huang
    Jun Zhu
    Wenbin Qian
    Weidong Han
    Aibin Liang
    Cancer Biology & Medicine, 2023, (02) : 129 - 146
  • [50] A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Yan, Zixun
    Sheng, Lingshuang
    Wang, Li
    Wu, Wen
    Zhang, Yilun
    Shen, Rong
    Cao, Weiguo
    Li, Lei
    Chen, Sheng
    Jiang, Xufeng
    Yi, Hongmei
    Song, Qi
    Wang, Li
    Cheng, Shu
    Xu, Peng-Peng
    Li, Jianyong
    Zhao, Weili
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)